Lantern Pharma Analyst Ratings
Lantern Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2022 | 162.53% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 759.19% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 711.46% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 663.72% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 472.79% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/01/2022 | 162.53% | EF Hutton | → 11 美元 | 启动覆盖范围开启 | → 购买 |
| 03/11/2022 | 759.19% | HC Wainwright & Co. | 34 美元 → 36 美元 | 维护 | 买 |
| 11/02/2021 | 711.46% | HC Wainwright & Co. | 32 美元 → 34 美元 | 维护 | 买 |
| 2021 年 7 月 10 日 | 663.72% | HC Wainwright & Co. | → 32 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 7 月 28 日 | 472.79% | 高力证券 | → 24 美元 | 启动覆盖范围开启 | → 购买 |
Lantern Pharma Questions & Answers
Lantern Pharma 问题与解答
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on November 1, 2022. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 162.53% upside). 3 analyst firms have reported ratings in the last year.
EF Hutton于2022年11月1日公布了Lantern Pharma（纳斯达克股票代码：LTRN）的最新目标股价。该分析公司将目标股价定为11.00美元，预计LTRN将在12个月内升至12个月内（可能上涨162.53％）。去年有3家分析公司公布了评级。
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma initiated their buy rating.
EF Hutton对Lantern Pharma（纳斯达克股票代码：LTRN）的最新分析师评级由EF Hutton提供，Lantern Pharma启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on November 1, 2022 so you should expect the next rating to be made available sometime around November 1, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Lantern Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Lantern Pharma的最新评级是在2022年11月1日公布的，因此您应该预计下一个评级将在2023年11月1日左右公布。
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a initiated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.19, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Lantern Pharma（LTRN）评级已启动，目标股价为0.00美元至11.00美元。Lantern Pharma（LTRN）目前的交易价格为4.19美元，在分析师的预测区间内。